Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 160 of 5804
-
Could a targeted immune blocker tame a deadly heart side effect of cancer drugs?
Disease control CompletedImmune-checkpoint-inhibitors (ICI) have revolutionized treatment for about 20 cancer types. They unleash anti-tumor immune responses. Unfortunately, in 0.36-1.23% of patients, this activation can also lead to lethal immune-related adverse events (irAEs) that can affect any organ.…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedResearchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulate…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Two-Drug cocktail targets Hard-to-Treat cancer mutation
Disease control OngoingThis is a phase 1/2, open label study of D-1553 in combination with IN10018 to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation
Phase: PHASE1, PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a targeted immune drug calm rare muscle inflammation?
Disease control CompletedThis study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certa…
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a Low-Dose immune calmer slow Alzheimer's decline?
Disease control OngoingStudy aims at evaluating the therapeutic efficacy and safety of low-dose IL-2 immunomodulatory treatment in patients with early AD, in a phase II, randomized, double blind, placebo-controlled phase II clinical trial. Patients with AD at early stage will be recruited and randomize…
Phase: PHASE2 • Sponsor: Centre Hospitalier St Anne • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New combo attack on leukemia shows promise in early trial
Disease control OngoingAcute lymphoblastic leukemia (ALL) is the most frequent cancer in children, decreases in adolescence and adulthood, and a second peak can be recorded starting from the 6th decade of life. While the outcome in children is excellent, in the adolescent/adult population, the prognosi…
Phase: PHASE2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy shows promise for saving rectal cancer Patients' anuses
Disease control CompletedAt present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective ra…
Phase: PHASE2, PHASE3 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a Two-Drug attack outsmart resistant breast cancer?
Disease control Recruiting nowThe aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.
Phase: PHASE1, PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill aims to ease sickle cell pain and boost hemoglobin
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New radiation treatment shows promise for tough skin cancers
Disease control OngoingThis is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radia…
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingIn this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus…
Phase: PHASE2, PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer?
Disease control OngoingThe primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-…
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Radioactive injection shows promise in slowing neuroendocrine tumor growth
Disease control OngoingThis was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\[177Lu\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differ…
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Hope for Alzheimer's psychosis: new drug aims to stop relapses
Disease control Recruiting nowThis is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug aims to stop NMOSD attacks in its tracks
Disease control OngoingThis study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug DON aims to protect brains of children with cerebral malaria
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are: * Evaluate the safety of a s…
Phase: PHASE1, PHASE2 • Sponsor: Douglas Postels, MD, MS • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Brain device zaps seizures in Tough-to-Treat epilepsy
Disease control CompletedTo demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
Phase: NA • Sponsor: NeuroPace • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Double-Drug attack on tough lung cancer mutation
Disease control CompletedThis study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could less be more? trial tests reduced radiation and chemo after surgery for HPV-Linked throat cancer
Disease control Recruiting nowThis is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery. Following surgery, patients will be classified as either low, intermediate, or high risk based on the characteristics of the tum…
Phase: PHASE2 • Sponsor: Heath Skinner • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain colorectal cancers
Disease control Recruiting nowColorectal cancer (CRC) is the 2nd to 3rd most common malignant disease in developed countries, with over 1 million new cases and 500,000 deaths worldwide each year. The primary treatment for early stage CRC is surgery to remove the tumour, which is possible in 80% of patients. E…
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC